Tissue plasminogen activator

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Friday, April 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on: 
Friday, February 2, 2024
CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points: 
  • TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
  • Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
  • In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
  • Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Retrieved on: 
Friday, February 2, 2024
CHI, CCNR, Stroke, BRIGHT, Patient, Tissue plasminogen activator, Brain, Therapy, Hope, Doctor of Philosophy, U.S. FDA, Pharmaceutical industry

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.

Key Points: 
  • TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke.
  • Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment.
  • In December 2023, CHI Memorial achieved a significant milestone by enrolling the first U.S. patient in the Lumosa 203, double-blinded stroke study.
  • Lumosa and CHI Memorial are committed to advancing medical innovation and improving the lives of stroke patients worldwide.

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
Tuesday, October 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Hypersensitivity, Status epilepticus, Intracerebral hemorrhage, Cerebral amyloid angiopathy, Arthralgia, Cerebral edema, Hypotension, Aneurysm, Risk, Focal neurologic signs, Chills, Fatal, Fever, Edema, Neuroimaging, AND, Angioedema, Siderosis, Tissue plasminogen activator, Aspirin, Hypertension, Vomiting, Incidence, Excipient, ARIA, Anticoagulant, MRI, Magnetic resonance imaging, Dizziness, Amyloid, Patient, Intraparenchymal hemorrhage, Anaphylaxis, Paracetamol, Seizure, Genetic testing, Confusion, Nausea, Observation, Lecanemab, Headache, Bronchospasm, Vascular malformation, Medical device, Pharmaceutical industry, Lace, Medical imaging, Copper

INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.

Key Points: 
  • INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.
    LEQEMBI is indicated for the treatment of Alzheimer’s disease.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Retrieved on: 
Monday, June 5, 2023
Columbia University, Central nervous system, Therapy, Senior, Doctor of Philosophy, Li Yang, Disability, Stroke, Nature Communications, Tissue plasminogen activator, Antibody, CNS, Incidence, BBB, Regeneration, MD, Division, Central nervous system disease, Stanford University School of Medicine, Death, Disease, Pharmaceutical industry, Vaccine, Hematology, Frizzled-4, WNT, Biology

Many central nervous system (CNS) disorders are characterized by abnormal BBB function, including ischemic stroke.

Key Points: 
  • Many central nervous system (CNS) disorders are characterized by abnormal BBB function, including ischemic stroke.
  • Adult ischemic stroke is a serious and prevalent health problem with a substantial incidence of stroke-related death and disability.
  • The importance of Fzd4 signaling for therapeutic BBB modulation is well known, although successful pharmacologic Fzd4 activation has remained elusive.
  • This publication describes 1) overcoming the challenges of systemic pharmacologic Fzd4 stimulation to develop an optimized, Fzd4 selective –Wnt mimetic antibody, and 2) results from administering this Fzd4 Wnt surrogate (L6-F4-2) in preclinical models of ischemic stroke.

Chromatography Resins Global Market Report 2022: Sector to Reach $3.1 Billion by 2027 at a CAGR of 6.71% - ResearchAndMarkets.com

Retrieved on: 
Friday, March 3, 2023
Chemicals, Plastics, Health, Manufacturing, Biometrics, Chromatography, Ion exchange, F&B, Prevalence, Drink, COVID-19, Food, Interferon, Tuberculosis, Insulin, Coronavirus, Cancer, Vaccine, DNA, Tissue plasminogen activator, Fine chemical

These insights are included in the report as a major market contributor.

Key Points: 
  • These insights are included in the report as a major market contributor.
  • Chromatography resins provide support to polysaccharide beads that are packed into a column.
  • The publisher provides an analysis of the key trends in each sub-segment of the global chromatography resins market report, along with forecasts at the global, regional and country level from 2022-2027.
  • Our report has categorized the market based on product, technique and end use.

Asia Pacific Glycomic Therapeutics Market Report 2023: Featuring Biomarin Pharmaceutical, Genzyme, Bayer, Glaxosmithkline & F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Glycosaminoglycan, Cataract, Bayer, Erythropoietin, GlaxoSmithKline, COVID-19, Enzyme replacement therapy, Government, Heparin, Precision medicine, Neuraminidase, Genzyme, Glycomics, Interferon, Glycoprotein, Alzheimer's disease, Proteoglycan, Gaucher's disease, Therapy, Center for Urban and Regional Analysis, Tissue plasminogen activator, Anemia, Research, Cancer, Thrombosis, Glycosphingolipid, GPI, ERT, Pharmaceutical industry, Fine chemical, Sanofi, Selectin

The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.

Key Points: 
  • The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.
  • The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
  • Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.
  • ; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
Tuesday, January 10, 2023
Cerebral edema, Intracerebral hemorrhage, Anticoagulant, Arthralgia, Aspirin, Stroke, MRI, Dizziness, Cerebral contusion, Seizure, Hypotension, Effectiveness, Status epilepticus, Diarrhea, Clopidogrel, Alzheimer's disease, Aneurysm, Risk, Vomiting, ARIA, Chills, AND, Disease, Nausea, Patient, Intracranial hemorrhage, Vascular malformation, Cough, Paracetamol, Hypertension, Focal neurologic signs, Headache, Observation, Incidence, Tissue plasminogen activator, Confusion, Siderosis, Fever, Medical device, Pharmaceutical industry, Medical imaging, Clothing

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.